Get started
AAA

MEDESIS PHARMA S.A.

No trades
See on Supercharts
Overview
Financials News Discussions Technicals Forecast Seasonals

ALMDP chart


Full chart

Key stats


Market capitalization
‪1.76 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
—
Net income (FY)
—
Revenue (FY)
—
Shares float
‪4.54 M‬
Beta (1Y)
1.34

About MEDESIS PHARMA S.A.


Sector
Health Technology
Industry
Biotechnology
CEO
Jean-Claude Maurel
Website
medesispharma.com
Headquarters
Baillargues
Founded
2003
ISIN
FR0010844464
FIGI
BBG00Z1FPLX7
Medesis Pharma SA operates as a clinical development stage biopharmaceutical company, which engages in the research and development of orally administered molecule drugs. The company was founded by Jean-Claude Maurel on April 3, 2004, and is headquartered in Baillargues, France.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ALMDP news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ALMDP is 0.340 EUR — it hasn't changed in the past 24 hours. Watch MEDESIS PHARMA S.A. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange MEDESIS PHARMA S.A. stocks are traded under the ticker ALMDP.
ALMDP stock hasn't changed in a week, the month change is a −22.22% fall, over the last year MEDESIS PHARMA S.A. has showed a −62.14% decrease.
We've gathered analysts' opinions on MEDESIS PHARMA S.A. future price: according to them, ALMDP price has a max estimate of 0.80 EUR and a min estimate of 0.80 EUR. Watch ALMDP chart and read a more detailed MEDESIS PHARMA S.A. stock forecast: see what analysts think of MEDESIS PHARMA S.A. and suggest that you do with its stocks.
ALMDP reached its all-time high on Feb 16, 2021 with the price of 18.000 EUR, and its all-time low was 0.307 EUR and was reached on Nov 27, 2024. View more price dynamics on ALMDP chart.
See other stocks reaching their highest and lowest prices.
ALMDP stock is 2.94% volatile and has beta coefficient of 1.34. Track MEDESIS PHARMA S.A. stock price on the chart and check out the list of the most volatile stocks — is MEDESIS PHARMA S.A. there?
Today MEDESIS PHARMA S.A. has the market capitalization of ‪1.76 M‬, it has increased by 2.65% over the last week.
Yes, you can track MEDESIS PHARMA S.A. financials in yearly and quarterly reports right on TradingView.
No, ALMDP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ALMDP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MEDESIS PHARMA S.A. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MEDESIS PHARMA S.A. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MEDESIS PHARMA S.A. stock shows the sell signal. See more of MEDESIS PHARMA S.A. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.